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Abstract
Transforming growth factor β -1, encoded by the TGFB1 gene, is a cytokine that plays a central role in many physiologic and pathogenic processes. We have sequenced TGFB1 regulatory region and assigned allelic genotypes in a large cohort of hematopoietic stem cell transplantation patients and donors. In this study we analyzed 522 unrelated donor-patient pairs and examined the combined effect of all the common polymorphisms in this genomic region. In univariate analysis, we found that patients carrying a specific allele, 'p001', showed significantly reduced overall survival (5-year overall survival 30.7% for p001/p001 patients vs 41.6% others; p=0.032) and increased non-relapse mortality (1-year non-relapse mortality:
39.0% vs 25.4%; p=0.039) after transplantation. In multivariate analysis, the presence of a p001/p001 genotype in patients was confirmed as an independent factor for reduced overall 
Introduction
Hematopoietic stem cell transplantation (HSCT) is a medical procedure used to treat malignant and non-malignant diseases of the blood, as well as solid tumors. The outcome of HSCT is influenced both by clinical and genetic factors. Compatibility between the recipient and their donor in terms of HLA is a well-known limiting factor for the success of allogeneic HSCT. 1 In addition, genes other than those of the HLA system, in particular those that are highly polymorphic, have been proposed as potential factors affecting the success of this therapy. 2 One of the genes that are likely to play an important role in the outcome of allogeneic HSCT is TGFB1, which encodes transforming growth factor-β1 (TGF-β1). TGF-β1 is a cytokine that plays a central role in many physiologic and pathogenic processes, having pleiotropic effects on cell proliferation, differentiation, migration and survival, as well as being a fundamental component of the immune system. TGF-β1 is likely to be relevant for both therapeutic and pathogenic immune processes associated with the different stages of HSCT. 3 Genetic variation resulting in differences in its production and/or function could play a role in the way that this cytokine modifies these immune processes.
Regulatory activity for this gene, located at chromosome 19q13.1-q13.3, has been mapped to approximately 3.0 kilobases (kb) from positions -2665 to +423 in its exon 1 (+1 being the translation start site). This region includes two promoter sites, two negative regulatory elements and two enhancers lying upstream of the first promoter. 4 Several polymorphisms in TGFB1 regulatory region have been identified, and these are known to cause alterations in cytokine secretion in several settings. 4 Previous work allowed for the definition of 17 TGFB1 regulatory region and exon 1 alleles, which are formed by the combination of 18 SNPs and other kinds of variation (Supplementary Table 1) . 4, 5 We have recently expanded this inventory of TGFB1 alleles with the discovery of other less common variant combinations. 6 The role of polymorphism in TGFB1 in the outcome of HSCT has been examined in some studies. 7 However, the results have not been consistent. In this study, we aimed at 
Non-stimulated and plate-bound antibody-stimulated cells were used as controls.
Statistical methods
The 
Results

Cohort
The cohort was composed of 522 unrelated myeloablative transplants performed between 1996 and 2009. Typing was possible for only patient or donor DNA for nine and 11 pairs, respectively. Although permission for genetic testing was granted, permission for clinical data use was not granted in 18 cases (patient TGFB1
genotypes: p001/p003 (n=7), p003/p003 (n=6), p001/p001 (n=2), p006/p014 (n=2), and p014/p014 (n=1)) and these were thus excluded. Consequently, when clinical data were analyzed the final number of pairs included for patient and donor genotypes were 493 and 495, respectively ('whole cohort'). The characteristics of the patients, their donors and the transplants are presented in Table 1 . T-cell depletion with alemtuzumab was used in 85% of the patients.
Descriptive results for the typing of TGFB1 regulatory region and exon 1 alleles in the patient-donor cohort
Only six of the previously reported alleles were seen in the cohort: p001, p003, p006, p009, p013, and p014, four of which were predominant (Table 2 ). Supplementary Table 5 shows the genotype frequencies observed. Neither the allele nor the genotype frequencies differed significantly between patients and donors (Z test; p>0.050).
Nine samples (five donors and four patients) showed genotypes that did not correspond with any allelic combination based on the previously known 17 TGFB1 regulatory region and exon 1 alleles. These samples were shown to carry a combination of a known allele and a novel allele. (95%CI=26.3-34.5%), respectively. Median OS was 21.6 months (95%CI=11.5-31.6 months). Median EFS was 9.9 months (95%CI=7.6-12.2 months). One-year cumulative incidence for NRM was 26.8% in the whole cohort. Five-year relapse cumulative incidence was 39.0%. Median time to relapse was 51.6 months (95%CI=9.5-93.8 months).
The effect of TGFB1 polymorphism on survival was assessed in three models:
recessive allelic, dominant allelic, and SNP (-1347C>T)-associated effects. Both the effect of donor and patient-borne polymorphism was independently assessed.
Recessive models
Variation in patient TGFB1 regulatory region and exon 1 had a significant effect on the OS of the whole cohort. When homozygosity for alleles p001 and p003 and heterozygosity were compared ( Figure 1A ), significant differences were found (n=486 when excluding patients homozygous for p006 and p014 due to low numbers; p=0.041). Patients homozygous for p003 (n=132) had the highest median OS (43.8 months), while patients homozygous for the p001 allele (n=41) had the lowest (7.9 months). When pairwise comparisons were considered, there was a significant difference between patients homozygous for p001 and p003 (p=0.014), and a trend between p001 and the heterozygous group (n=313; p=0.071). Patients with a p001/p001 genotype (n=41) show significantly lower OS than the rest of the patients of any other genotype (n=452; 5-year OS 30.7% for p001/p001 patients vs 41.6% others; p=0.032) ( Figure 1B ).
No differences in OS according to donor allele were found (n=491; p=0.47). Other
TGFB1 alleles could not be tested due to low numbers of homozygotes. Among all patient genotypes with n>20, only p001/p001 shows a significant effect on OS in the whole cohort when compared to the rest of the genotypes (data not shown). 1 
Dominant models
No effect of patient alleles was seen using this model ( Figure 1C for p001). However, patients whose donors carried at least one copy of p001 had worse OS than patients whose donor lacked this allele (median OS 13.7 vs. 39.5 months, respectively, p=0.043). Alleles p003, p006 and p014 did not have statistically significant dominant donor effects on OS in this cohort.
TGFB1 -1347C>T (rs1800469)
The -1347T variant was close to a marker for allele p001 in this cohort (41/43 TGFB1 -1347TT patients were p001/p001). There was no statistical evidence for a recessive effect of either patient (n=493; p=0.11) or donor (n=495; p=0.11) genotype on OS 
Analysis of EFS, NRM, relapse and aGVHD
There was a significant increase in the incidence of NRM among patients that bear the p001 allele (1-year NRM: 39.0%; p=0.039) or the -1347T (1-year NRM: 39.5%; p=0.029) in a homozygous manner when compared to other genotypes (1-year NRM:
25.4% and 25.3%, respectively) ( Figure 3A-C) . There was no effect of the dominant presence of p001 among donors ( Figure 3D) .
None of the models tested impacted on EFS, disease relapse or aGVHD (grades I-IV, II-IV or III-IV).
Multivariate analyses
Based on the univariate analyses for the clinical factors ( For NRM patient homozygosity for TGFB1 p001 (or -1347T), patient age older than 40 years, and the presence of 1 or more allelic HLA mismatches (i.e. ≤ 9/10) were associated with increased probability of death (Table 4) .
Functional consequences of TGFB1 regulatory region and exon 1 alleles in Treg
When Treg from healthy donors were stimulated with antibodies against CD3 and CD28, an upregulation of surface LAP, which peaked at 24 h of culture, was detected. This upregulation was observed only on the CD4+, CD127lo cells and CD25+ cells as previously described. 8 As shown in Figure 4 , TGFB1 genotype appears to influence the levels of LAP expressed by Treg upon TCR stimulation. A trend towards higher LAP+ levels was seen when the sample expressed a p001 allele (Mann-Whitney test; p=0.07). An analysis of p001/p001 individuals on their own was not possible because of the reduced frequency of this genotype among available healthy volunteer donors.
Discussion
The present study revealed that homozygosity for a TGFB1 p001 allele in UD-HSCT patients was associated with significantly worse OS and NRM. Cellular experiments suggest a potential functional effect of TGFB1 p001, as there was a trend toward higher expression of surface TGF-β1 on in vitro stimulated Treg that bore this allele.
This study is the largest performed so far on the role of TGFB1 polymorphisms in HSCT. In contrast to previous studies, the analysis encompassed the combined effect of various polymorphisms organized in defined alleles in a genomic region of approximately 3 kb.
A few studies have analyzed TGFB1 polymorphism in HSCT but their heterogeneity makes comparisons difficult. 7 Most previous studies are small (54% included less than 100 pairs), or have investigated rare alleles. Moreover, most of the studies have focused their analysis on one or two SNPs and only on their impact on GVHD. Two early studies also used pre-existing classifications of the genotypes in "high producer" and "low producer" groups, potentially introducing a bias in their analyses.
9-11
Studies in mostly related donor cohorts have found no association for TGFB1 +29T>C and +74G>C or their combined +29~+74 genotypes with OS, GVHD, engraftment or infections. 9, 12 In a larger study with mismatched UD-HSCT there was no consistent association of TGFB1 -1347C>T with OS, engraftment or GVHD despite initial findings in a discovery cohort. 13 Finally, in two recent reports analyzing relatively large cohorts of mostly related donor transplants TGFB1 -1347 TT and CT patients showed increased incidence of aGVHD, but no effect on OS, EFS, or NRM. 14, 15 TGFB1 -1347T was found to be a risk factor for skin aGVHD but protective against lung cGVHD.
15
In our analyses, there was no statistical confirmation of a role of +29T>C 16 (data not shown). An explanation for this difference could be the fact that +29CC genotypes could include both p001 and p014. 1 4 a recessive effect in our cohort. However, since OS in +29CC patients was not statistically different from +29TT and TC individuals, this could be evidence toward the lack of effect from p014. Of note, a study performed in Chinese HSCT patients (n=240) found lower incidence of aGVHD in patients whose donors were TGFB1 -1347TT individuals, and also in patients who bore at least one copy of the T variant, but with no effect on OS, NRM or relapse. 17 However, it is uncertain if TGFB1 -1347T
correlates with allele p001 in the Chinese population.
In the present study, the effect seen for allele p001 on OS and NRM could not be explained by increases in the incidence of aGVHD. This might be due to the fact that most of the transplants included in our cohort were T cell-depleted, and the incidence of aGVHD was low. Despite this, there remains the possibility that this cytokine could modify this complication for example by affecting the generation of Th17 cells. 18 Alternatively, the genetic association with NRM could potentially be explained by another cause of death in which TGF-β1 might play a role, such as impaired early immune responses to infectious agents, 19 organ damage, 20 or complications such as hepatic veno-occlusive disease. 21 However, this remains unclear. Interestingly, a recent report 22 has shown evidence of a role for TGF-β1 in limiting both the growth and function of the thymic medulla, another potential niche for its influence on the outcome of HSCT.
Our typing results revealed that four TGFB1 regulatory region and exon 1 alleles predominated. Even though this was not a population study, our results provide insight into TGFB1 regulatory region allelic diversity and frequencies and are a potential reference for future studies. Overall, the frequencies for variant polymorphic positions and for TGFB1 regulatory region and exon 1 alleles agree widely with partial data previously reported by other studies. 23 We speculated that the strong detrimental effect of patient p001 observed in this study was related to differences in functionality between TGFB1 regulatory region and exon 1 alleles. Our study showed that the level of surface TGF-β1 on Treg after 1 5 TCR stimulation appears to be modified by the presence of the p001 allele in TGFB1.
Even though it did not reach statistical significance, TGFB1 p001/x genotypes showed results that suggested higher generation of LAP+ cells when compared to TT individuals, following previous observations in other cell types and experimental systems.
The -1347T variant has been previously associated with higher TGF-β1 plasma levels 24 , as well as with a significant increase in in vitro TGF-β1 expression 25 via alteration of promoter interactions with transcription factors Yin Yang 1 26 and AP1. 27 Combining both the observations made for TGFB1 -1347C>T and those made for +29T>C, 28 Shah et al. proposed that TGFB1 alleles that share a -1347T and +29C
would represent a high production phenotype. 4 Allele p001 would be the sole representative of this cluster seen with significant frequencies in our cohort. Of note, a couple of studies have found opposite results and associated -1347T and +29C
with lower plasma concentrations of this cytokine and lower reporter gene activities 29 , and a TGFB1 upstream haplotype congruent with allele p001 with weaker promoter activity than another haplotype fitting with allele p003. 30 However, the genomic region examined in the latter study only partially spanned the one studied here and included different SNPs not characterized in this study. Finally, one study associated allelic variants carrying a proline either in codon 10 (+29C) or 25 (+74C) with reduced expression, but only included TGFB1 coding region in in vitro constructs. 31 In addition to a -1347T variant, a feature that is unique to p001 is the absence of the -2389AGG duplication (rs11466313), and this has been associated with the gain of allele DNA-protein complexes, potentially leading to novel transcription factor binding site motifs. 30 Low frequency of homozygotes for some of the TGFB1 alleles precluded thorough analysis of their effects. A substantially larger study would be needed for it to be possible to assess homozygous individuals. In addition, since our cohort was comprised mainly of alemtuzumab-T cell-depleted transplants, changes in its dosage 1 6 or dosage schedule could have taken place over the 13-year observation period, potentially having an impact on our results. Unfortunately, this information is not available for assessment. Finally, we do not have data on replication of these results in an independent cohort. Hence, these analyses should be confirmed also considering other settings such as non-myeloablative transplants or transplants performed with alternative donors.
In conclusion, the fact that patients having a p001/p001 genotype have significantly higher probabilities of dying early after the transplant could potentially allow for better preemptive measures to improve the prognosis for these patients. However, further research is needed to understand the mechanism of this effect and the cause(s) of death associated with it. BM, bone marrow; CMV, cytomegalovirus; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; MTX, methotrexate; NRM, non-relapse mortality; OS, overall survival; PB, peripheral blood; SC, stem cell; TBI, total body irradiation. 1 
Supplementary methods
HSCT patient and donor samples were subjected to typing using the strategy described in (6) . In brief, genomic DNA was used to separately amplify 4 sub-regions of TGFB1's regulatory region and exon 1. These 4 amplicons were then purified in order to be used as templates for bidirectional Sanger sequencing using the M13 tags attached to the amplification primers. The sequences were then analyzed and the genotypes for each of the 18 basic polymorphic positions were recorded and input in a database. Additionally, the rest of the sequence was scanned for the presence of potentially novel polymorphisms outside the basic 18 sites. Based on the genotype at these basic polymorphic positions and the alleles previously described in isolation by Shah and collaborators (4,5, Supplementary In cases where theoretical ambiguities existed, the phase of the relevant polymorphic positions was defined by allele-specific amplification strategies using different primer combinations as described in (6) . For example, when the genotype included a heterozygous result for the -2389dupAGG, then the -2389dupAGG-specific primers were used instead of the generic forward primer in combination with any of the reverse primers. The choice of reverse primer depended on the location of the relevant polymorphisms in order to create a -2389AGG-specific amplicon that would set their phase. Likewise, the +29 T>C-specific primers were also used to amplify either the +29T-bearing or the +29C-bearing allele and set the phase of other relevant polymorphisms that would define the allelic combination. This strategy was also used in the validation stages for the typing protocol using samples from healthy volunteer donors and whole-region amplification, prior to the typing of the clinical samples.
Ten percent of the patient and donor samples were selected to confirm their typing results.
For this, a new amplification from the stock DNA was carried out and sequencing of Region IV was repeated. All of these samples had results that were consistent with the original ones. Deviation from Hardy-Weinberg equilibrium (HWE) was tested for 5 of the SNPs (Supplementary table 3) . The two most infrequent polymorphisms were excluded because of their rarity. From polymorphisms that show the same observed genotypic frequencies (i.e.
-2389dupAGG and -1347C>T, and -768insC and +74G>C) only one was selected. TGFB1
+29T>C showed a significant deviation from HWE (p=0.03) caused by an excess of heterozygotes.
Deviation from HWE was also tested for the 4 major TGFB1 regulatory region and exon 1 alleles (Supplementary table 4) . The genotypic distributions were found not to be significantly deviated from expected frequencies (p>0.25).
These polymorphic positions allowed for the definition of the allelic genotypes for each patient-donor pair. Among the 17 previously defined regulatory region and exon 1 alleles, only 6 were seen in the cohort: p001, p003, p006, p009, p013, and p014. +74  +91  p001  A  -C  G  T  G  TT  C  G  G  -C  C  C  G  C  G  T  p002  ---A  ----------- ----C  -------------p011  ----C  ----------T  --p012  ------del  -----------p013  G  AGG  --C  -del  --------T  --p014  -AGG  --C  -----C  -----C  -p015  G  AGG  -----------G  -T  --p016  G  AGG  -------------T  --p017  G  ---C  ----------T .
